Quest Diagnostics (DGX)Officer sold ~$1.49M

~$1.49M

Approx. value · 7,946 sh @ $187.35

7,530

Holds after · shares reported

Traded

Nov 18, 2025

Filed

Nov 20, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Apr 28, 2025CongressDisclosed purchase of DGX — reported range $1,001 - $15,000
2. Jul 24, 2025CongressDisclosed sale of DGX — reported range $1,001 - $15,000
3. Sep 23, 2025InsiderOfficer sold ~$5.29M of DGX shares in the open market
4. Sep 24, 2025InsiderOfficer sold ~$33K of DGX shares in the open market
5. Sep 26, 2025Insider · 1 personInsiders: 2 sales (~$43K)
6. Oct 21, 2025Company filing · Form 8-K · ResultsReported its results
7. Oct 22, 2025InsiderDirector sold ~$270K of DGX shares in the open market
8. Nov 3, 2025CongressDisclosed sale of DGX — reported range $1,001 - $15,000
9. Nov 18, 2025 · this disclosureInsider · Their largest sale since 2024Officer sold ~$1.49M of DGX shares in the open market

What came next

1. Nov 25, 2025Insider · 2 peopleInsiders: 4 sales (~$10.8M)
2. Jan 12, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
3. Feb 10, 2026Company filing · Form 8-K · Results, Other newsReported its results, and reported other company news
4. Feb 10, 2026InsiderOfficer sold ~$1.16M of DGX shares in the open market
5. Feb 13, 2026Insider · 1 personInsiders: 5 sales (~$5.4M)
6. Feb 19, 2026Insider · 3 peopleInsiders: 3 sales (~$717K)
7. Mar 2, 2026InsiderCEO sold ~$2.13M of DGX shares in the open market
8. Mar 3, 2026Insider · 3 peopleInsiders: 3 sales (~$326K)
9. Mar 4, 2026InsiderOfficer sold ~$538K of DGX shares in the open market
10. Mar 5, 2026Insider · 3 peopleInsiders: 3 sales (~$2.5M)
11. Mar 9, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On March 9, 2026, the Board of Directors (the “Board”) of Quest Diagnostics Incorporated (the “Company”), after considering the recommendation of the Board's Governance Committee, elected Timothy Wentworth, former chief executive officer of Walgreens Boots Alliance, as a director.”

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Quest Diagnostics

For Quest Diagnostics, OQRO holds 5 insider filings (SEC Form 4 or Form 144), 5 Congress trade reports, 12 fund holdings reports (13F) and 7 federal contract awards dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its DGX page.

Other recent filings by Mark E Delaney, SVP & Chief Commercial Officer

• SEC Form 4 at Quest Diagnostics (DGX)Jul 29, 2026
• SEC Form 4 at Quest Diagnostics (DGX)May 14, 2025
• SEC Form 4 at Quest Diagnostics (DGX)May 14, 2025
• SEC Form 4 at Quest Diagnostics (DGX)Feb 7, 2025

The full history of Mark E Delaney, SVP & Chief Commercial Officer is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Quest Diagnostics

• USAspending.gov award recordOct 1, 2026
• USAspending.gov award recordOct 1, 2026
• USAspending.gov award recordOct 1, 2026
• USAspending.gov award recordOct 1, 2026
• USAspending.gov award recordSep 29, 2026
• SEC Form 4Sep 3, 2026

Everything OQRO holds on this company is on its DGX page.